The results published in eClinicalMedicine include a statistically significant and clinically relevant kidney-protective effect of RMC-035 compared to placebo in a stable phase after surgery. This effect is measured both as improved kidney function (estimated glomerular filtration rate, eGFR) at 90 days after surgery and as a reduction in Major Adverse Kidney Events (MAKE) at the same time point. MAKE is the expected primary efficacy endpoint in a future pivotal phase 3 study as required by regulatory authorities.
 
”We are very pleased to present the main results of the AKITA study in such a respected scientific journal as eClinicalMedicine. The publication validates the significance of the AKITA study and the efficacy signal observed for the first time in patients, associated with the completely new mechanism that RMC-035 represents,” said Guard Therapeutics CEO Tobias Agervald. 
 
The article, titled Efficacy of therapeutic alpha-1-microglobulin in reducing kidney injury after cardiac surgery: a randomized placebo-controlled Phase 2 study, was authored by Dr. Alexander Zarbock, the global principal investigator for the AKITA study and Professor of anesthesiology and intensive care medicine at the University Hospital of Münster, Germany. Co-authors are Tobias Agervald and Michael Reusch, CMO at Guard Therapeutics, as well as Nicolas Noiseux, David Mazer, Johannes Böhm, Maxime Laflamme, Klaus Matschke, Jan Burkert, Benoit de Varennes, Jan Vojacek, Jay L. Koyner, Dan Engelman and Matthias Thielmann.
 
”The results of the AKITA study are very exciting and indicate a potential breakthrough for the treatment of kidney injury associated with open-heart surgery. The concordance between improved renal function and the reduction of MAKE at a stable phase after surgery is very promising, as these endpoints reflect different ways of assessing the kidney-protective treatment effect. We look forward to the next development steps of RMC-035 and ultimately its potential to improve patient outcomes in the future,” said Professor Zarbock.
 
The next step in the clinical program for RMC-035 is a phase 2b study (POINTER) aimed at optimizing the dose and identifying the exact target patient population prior to a pivotal phase 3 study. Patient recruitment was recently initiated and is expected to take approximately one year. Overall study results are anticipated to be available about 6 months after the completion of patient recruitment.
 
The article is now available online via the following link:
Efficacy and safety of therapeutic alpha-1-microglobulin RMC-035 in reducing kidney injury after cardiac surgery: a multicentre, randomised, double-blind, parallel group, phase 2a trial - ScienceDirect